Shopping Cart
- Remove All
- Your shopping cart is currently empty
Venadaparib (NOV140101) (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib is insensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSBs) and can be used in solid tumor research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $41 | In Stock | |
2 mg | $57 | In Stock | |
5 mg | $97 | In Stock | |
10 mg | $147 | In Stock | |
25 mg | $297 | In Stock | |
50 mg | $488 | In Stock | |
100 mg | $716 | In Stock | |
1 mL x 10 mM (in DMSO) | $97 | In Stock |
Description | Venadaparib (NOV140101) (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib is insensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSBs) and can be used in solid tumor research. |
Targets&IC50 | PARP1:0.5 nM(EC50), PARP1/PARP2:1.4 nM/1.0 nM |
In vitro | Venadaparib significantly inhibits PARP1-mediated PAR expression with an EC50?of 0.5 nM In DNA damage-induced Hela cells[1]. |
In vivo | Oral administration of Venadaparib significantly inhibits PAR(>90%) in tumor tissues until 24 hr post-dose in the germline BRCA1-mutated ovarian cancer PDX model. Venadaparib also dose-dependently inhibits potent tumor growth compared to the Olaparib treatment group[1]. |
Alias | NOV140101, IDX-1197 |
Molecular Weight | 406.45 |
Formula | C23H23FN4O2 |
Cas No. | 1681017-83-3 |
Smiles | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CC(CNC2CC2)C1 |
Relative Density. | 1.43 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 90 mg/mL (221.43 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.